SEC Form 4 · accession 0001179110-18-014136

ENDOCYTE INC · ECYT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Vice President of Research

Period of report

Dec 17, 2018

Accepted (ET)

Dec 19, 2018 · 4:14 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001235007

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Dec 17, 2018	M	20,000	$2.54	A	142,482	D
Common Stock	Dec 17, 2018	M	26,177	$3.82	A	168,659	D
Common Stock	Dec 17, 2018	M	13,089	$7.49	A	181,748	D
Common Stock	Dec 17, 2018	M	22,500	$9.05	A	204,248	D
Common Stock	Dec 17, 2018	M	20,004	$3.55	A	224,252	D
Common Stock	Dec 17, 2018	M	2	$5.10	A	224,254	D
Common Stock	Dec 17, 2018	M	2	$3.18	A	224,256	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F2	$2.54	Dec 17, 2018	M	20,000	D	—	Mar 5, 2019	Common Stock	20,000	0	D
Stock Option (right to buy)^F2	$3.82	Dec 17, 2018	M	26,177	D	—	Feb 11, 2020	Common Stock	26,177	0	D
Stock option (right to buy)^F2	$7.49	Dec 17, 2018	M	13,089	D	—	Mar 11, 2021	Common Stock	13,089	0	D
Stock Option (right to buy)^F2	$9.05	Dec 17, 2018	M	22,500	D	—	Apr 14, 2021	Common Stock	22,500	27,500	D
Stock option (right to buy)^F2	$3.55	Dec 17, 2018	M	20,004	D	—	Feb 28, 2022	Common Stock	20,004	59,996	D
Stock option (right to buy)^F2	$5.10	Dec 17, 2018	M	2	D	—	Feb 4, 2025	Common Stock	2	52,498	D
Stock option (right to buy)^F3	$3.18	Dec 17, 2018	M	2	D	—	Feb 4, 2026	Common Stock	2	52,498	D

F1Includes 263 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018.
F2The option is fully vested and immediately exercisable.
F3Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017.